genel tıp derg Genel Tıp Dergisi 2602-3741 Selcuk University Dirençli granülomatöz polianjiitis olgusu Limon Muhammet Selçuk Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Konya Gülcemal Semral Selçuk Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Konya Kanat Fikret Selçuk Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Konya Yılmaz Sema Selçuk Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Konya 03 01 2019 29 2 95 98 Copyright © 1990, Genel Tıp Dergisi 1990 Genel Tıp Dergisi

Vasculitis is a heterogeneous group of diseases characterized by inflammatory destruction of blood vessels. Vasculitis may result different clinical syndromes according to the characteristics of vasculitis. Vasculitides are separated as primers and secondary in the frequently used classification system, primer vasculitis is separated as small, mediıum and large vessel vasculitis according to its vascular involvement. Granulomatosis polyangitiis GPA is a small vessel vascülitis associated with ANCA. GPA may be seen with limited and systemic involvement. We presented this case to share treatment and side effects in cases of limited and systemic GPA

Vaskülitler, kan damarlarının inflamatuvardestrüksiyonu ile karakterize heterojen bir grup hastalıktır. Vaskülitler tutulan damar özelliğine göre klinik bulgu verebilir. Primer vaskülitler damar tutulum özelliklerine göre büyük, orta ve küçük damar vasküliti olarak ayrılır. Granülomatöz polianjiitis GPA ANCA ilişkili küçük damar vaskülitidir. GPA sınırlı ve sistemik tutulumla seyredebilir. Bu olgu, akciğer tutulumu olan sistemik ve sınırlı GPA olgularında tedavive yan etkileri paylaşmak için sunulmuştur

 Vaskülit hemoptizi granülomatöz polianjiitis Vasculitis hemoptysis granulomatosis polyangitiis Jenette JC, Folk RJ, Bacon K, et al. 2012 revised Interna- tional ChapelHillConsensus Conference Nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11. Kallenberg CG. Antineutrophil cytoplasmic autoanti- body-associated small-vessel vasculitis. Curr Opin Rheu- matol 2007; 19. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improvedoutcome in Wegener’sgranulomatosisandmic- roscopicpolyangiitis? A retrospectiveanalysis of 95 cases in twocohorts. J InternMed 2009; 265:496-506. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-18. Girard T, Mahr A, Noel LH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener’s granulomatosis? A prospectivestudy. Rheumato- logy (Oxford) 2001;40:147–51. Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and mye- loperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002; 17: 2077–80. Jayne D. Treatment of ANCA-associated systemic small vessel vasculitis. APMIS Suppl 2009; 127::3-9. Puécha X, Pagnoux C, Perrodeau É, et al. Long-term outco- mes among participants in the WEGENT trial of remissi- on-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arth- ritis Rheumatol 2016;68:690–701. Carruthers D, Sherlock J. Evidence-based management of ANCA vasculitis. Best Pract Res Clin Rheumatol 2009; 23:367-78. Jayne D. Review article: Progress of treatment in ANCA-as- sociated vasculitis. Nephrology 2009;14:42-8. Pallan L, Savage CO, Harper L. ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol 2009;5:278-86. Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001;13:12–7. Kobayashi S, Inokuma S. Intrapulmonary hemorrhage in collagen-vascular diseases includes a spectrum of under lying conditions. Intern Med 2009;48:891-7. Stone JH, Merkel PA, Spiera R, et al. RAVE-ITN research group, Rituximab versus cyclophosphamide for ANCA-as- sociated vasculitis. N Engl J Med2010:15;363:221. Puéchal X.Targeted immunotherapy strategies in AN- CA-associated vasculitis. Joint Bone Spine 2019;86:321-6. Smith R, Jones R, Specks U, et al. Rituximab as re-induction therapy in relapsing ANCA-associated vasculitis [abstract]. Arthritis Rheumatol 2017;69:18. Wegener’s Granulomatosis Etanercept Trial (WGET) Rese- arch Group. Etanercept plus standard therapy for Wegener’s granulomatosis. NEngl J Med 2005,352:351.